Arcutis Biotherapeutics, Inc. has approved 61,000 restricted stock units to welcome nine new employees under its 2022 Inducement Plan. This move underscores the company’s dedication to attracting and retaining top professionals in the competitive field of immuno-dermatology.

Arcutis Biotherapeutics has enrolled the first child in an open-label Phase II clinical trial to evaluate the efficacy of Zoryve (roflumilast) cream 0.05% for treating atopic dermatitis in infants. The INTEGUMENT-INFANT trial represents a significant step toward addressing a prevalent inflammatory skin condition among young children.